New chickenpox shot shows promise in toddler trial
NCT ID NCT06806137
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new chickenpox vaccine in 600 healthy toddlers aged 12-15 months. The children receive two doses, and the new vaccine is compared to the current standard, Varivax. The goal is to see if the new vaccine produces a strong immune response and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Investigational varicella vaccine (VNS Vaccine)
- What this could lead to
- If successful, this could provide a safe and effective alternative chickenpox vaccine for young children.
- What could go wrong
- This is a Phase 3 trial, but it's still testing a new vaccine. It may not prove to be as effective or safe as the existing vaccine, and results may not apply to all children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHICKENPOX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
RECRUITINGSalvaleón de Higüey, La Altagracia Province, 23000, Dominican Republic
-
GSK Investigational Site
RECRUITINGConstanza, 11201, Dominican Republic
-
GSK Investigational Site
RECRUITINGSanto Domingo Oeste, 11906, Dominican Republic
-
GSK Investigational Site
RECRUITINGSan Pedro Sula, 21104, Honduras
-
GSK Investigational Site
RECRUITINGTegucigalpa, 11101, Honduras
-
GSK Investigational Site
RECRUITINGTegucigalpa, 2449, Honduras
More trials for these conditions
Other studies related to the condition(s) this trial covers.